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A 54-year-old woman presented with locally advanced pul-monary adenocarcinoma in December 2011. During the 
workup, lung mass increased rapidly and a large amount of 
pleural effusion was newly developed. The analysis of pleu-
ral effusion indicated malignant hemothorax, and more than 
1 liter of bloody pleural effusion was drained daily through a 
chest tube.
In the biomarker analysis, immunohistochemistry (IHC) 
with an antibody (clone 5A4, Novocastra, Newcastle, United 
Kingdom) for anaplastic lymphoma kinase (ALK) protein 
showed moderately positive staining (Fig. 1A). However, fluo-
rescent in situ hybridization (FISH) using a probe specific to 
the ALK locus (Vysis LSI ALK dual-color, break-apart rear-
rangement probe; Abbott Molecular, Abbott Park, IL) did not 
show ALK translocation (Fig. 1B). There was neither ROS1 
rearrangement nor MET amplification.
We started chemotherapy with gemcitabine plus cispla-
tin. The follow-up chest radiograph and computed tomogra-
phy, performed on the 17th day after starting chemotherapy, 
showed an unresolved primary lung mass and a mediastinal 
lymph node compressing the right main bronchus (Fig. 2A). 
We prescribed crizotinib (250 mg twice a day), starting 
February 16, 2012. The pleural effusion decreased rapidly, 
and the chest tube was removed 6 days after the initiation of 
crizotinib therapy.
At day 32, chest images showed a great decrease in the 
cancerous lesions (Fig. 2B). The patient did not experience 
any noticeable hematologic or nonhematologic adverse 
events. At day 83, the lesions decreased further; this partial 
response was confirmed with chest images (Fig. 2C). At 27 
weeks, the patient is still on crizotinib and is in good general 
condition.
DISCUSSION
Crizotinib is now approved for the treatment of 
ALK FISH-positive advanced non–small-cell lung cancer 
(NSCLC), based on two pivotal studies performed among 
the FISH-identified population.1,2 However, some important 
shortcomings of the ALK FISH assay have been reported. 
First, because the splitting of the red (3′) and green (5′) signals 
can be extremely subtle, false-negative results are sometimes 
reported.3 Second, the noninterpretation rate in FISH tests 
among tumors, which were reported as ALK-positive by IHC 
analysis was considerably high.4
ALK IHC was validated as a screening tool before the 
FISH assay for the detection of ALK rearrangement. The 
reported concordance rate for ALK positivity between IHC 
and FISH is consistently high.4,5 However, ALK positivity was 
not reproduced by FISH in some ALK IHC-positive cases.4,5 
Before our report, the clinical relevance of crizotinib therapy 
in the ALK IHC-positive and FISH-negative tumors subgroup 
was not known.
We ruled out the possibility in our case that crizotinib 
showed its effectiveness by affecting the MET or ROS1 path-
ways by demonstrating no aberrancy of these genes. However, 
we did not reevaluate ALK positivity by reverse transcription 
polymerase chain reaction, another sensitive method for the 
detection of ALK-positive NSCLC. However, reverse tran-
scription polymerase chain reaction for ALK rearrangement 
is not routinely performed in daily practice because it requires 
highly qualified RNA.
Considering its affordability and sensitivity, an IHC-
based ALK test may represent a reliable and cost-effective 
screening strategy in detecting patients who might benefit 
from crizotinib. Our case supports the need for large-scaled 
biomarker studies to identify the best diagnostic strategy for 
ALK-positive NSCLC.
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FIGURE 1. A, Immunohistochemistry 
showed moderate ALK protein expres-
sion, B, FISH analysis did not show 
any translocation of ALK gene. ALK, 
anaplastic lymphoma kinase; FISH, 
fluorescent in situ hybridization.
FIGURE 2. A, Chest radiograph and 
computed tomography at baseline 
of crizotinib therapy revealed a large 
primary lung mass and mediastinal 
lymph nodes with a chest tube in situ. 
B, Chest images checked at day 32, 
and C, at day 83 of crizotinib therapy 
showed significantly decreased tumor.
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